South America Intravenous Immunoglobulin Market Forecast to 2028 – COVID-19 Impact and Regional Analysis – by Type (Carmine, Anthocyanins, Caramel, Curcumin, Annatto, Carotenoids, Chlorophyll, and Others), Form (Liquid & Gel and Powder), and Application (Bakery and Confectionery, Dairy and Frozen Desserts, Beverages, Sauces; Dressings; and Condiments, RTC and RTE Products, Meat; Poultry and Seafood, and Others)   

The intravenous immunoglobulin market in SAM is expected to grow from US$ 783.22 million in 2022 to US$ 1,167.28 million by 2028. It is estimated to grow at a CAGR of 6.9% from 2022 to 2028.

Increasing Geriatric Population

Many of the patients treated with IVIG are above the age of 60 years. With aging, the ability to produce T-cells to fight diseases gets significantly reduced. Thus, an older person’s body is easily prone to several infections and diseases, which increases the demand for immune therapies that involve the use of IVIg. Thus, the increase in the geriatric population across the region is bolstering the intravenous immunoglobulin market.

Market Overview

The SAM intravenous immunoglobulin market is segmented into Brazil, Argentina, and the Rest of SAM. The region held the smallest portion of the market in the global analysis. The intravenous immunoglobulin market in the region is expected to have growth opportunities during the forecast period. The intravenous immunoglobulin market in the SAM region is expected to grow, owing to increased cases of autoimmune diseases and immunodeficiencies, surge in various research activities, increase in awareness, and rise in healthcare expenditure by the countries of the region. Brazil has made huge strides in the healthcare sector, owing to increasing healthcare expenditure. As per the International Trade Administration (ITA), Brazil is the largest healthcare market in Latin America, and it spent 9.1% of its GDP on healthcare in 2020. The intravenous immunoglobulin market in Brazil is expected to flourish, owing to factors such as surge in vaccination programs and rise in healthcare expenditure by the country.

SAM Intravenous Immunoglobulin Market Revenue and Forecast to 2028 (US$ Million)

SAM Intravenous Immunoglobulin Market Segmentation 

The SAM intravenous immunoglobulin market is segmented into type, application, distribution channel, end user, and country. Based on type, the market is segmented into IgG, IgM, IgA, IgE, and IgD. The IgG segment registered the largest market share in 2022.

• Based on application, the SAM intravenous immunoglobulin market is segmented into hypogammaglobulinemia, chronic inflammatory demyelinating polyneuropathy (CIDP), immunodeficiency diseases, myasthenia gravis (MG), multifocal motor neuropathy (MMN), idiopathic thrombocytopenic purpura (ITP), inflammatory myopathies, specific antibody deficiency (SDA), Guillain-Barre syndrome (GBS), and others. The immunodeficiency diseases segment registered the largest market share in 2022.
• Based on distribution channel, the SAM intravenous immunoglobulin market is segmented into hospital pharmacy, retail pharmacy, and others. The hospital pharmacy segment registered the largest market share in 2022.
• Based on end user, the SAM intravenous immunoglobulin market is segmented into hospitals, specialty clinics, and others. The hospitals segment registered the largest market share in 2022.
• Based on country, the market is segmented into Brazil, Argentina, and the Rest of SAM. Brazil dominated the market in 2022.
• ADMA Biologics, Inc.; Bio Products Laboratory Ltd.; CSL Behring (CSL Limited); Grifols, S.A.; Kedrion S.p.A; Octapharma AG; Pfizer Inc.; Prothya Biosolutions B.V.; Shanghai RAAS; and Takeda Pharmaceutical Company Limited are among the leading companies operating in the intravenous immunoglobulin market in the region.  

1. ADMA Biologics, Inc.
2. Bio Products Laboratory Ltd.
3. CSL Behring (CSL Limited)
4. Grifols, S.A.
5. Kedrion S.p.A
6. Octapharma AG
7. Pfizer Inc.
8. Prothya Biosolutions B.V.
9. Shanghai RAAS
10. Takeda Pharmaceutical Company Limited

• Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the SAM intravenous immunoglobulin market.       
• Highlights key business priorities in order to assist companies to realign their business strategies
• The key findings and recommendations highlight crucial progressive industry trends in the SAM intravenous immunoglobulin market, thereby allowing players across the value chain to develop effective long-term strategies
• Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
• Scrutinize in-depth SAM market trends and outlook coupled with the factors driving the intravenous immunoglobulin market, as well as those hindering it
• Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution